MOLECULAR TARGET AND THERAPEUTIC ASPECTS OF RHEUMATOID ARTHRITIS: A REVIEW.

Authors

  • Biswaranjan Das
  • Subir Samanta

Abstract

 

Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease. Cytokine plays a significant role in modulating the immune system
and specifically the inflammation. The role of cytokines in disease has led to new development in the treatment of inflammatory diseases. Different
mediator cause inflammation, and degradation of joint cartilage in RA. Some of the novel target inhibitors, which are used to treat and control this
disease are cyclooxygenase-2, tumor necrosis factor-α (TNF-α), TNF-α converting enzyme, interleukin-1, 6, 8, 10, 12, 15, 18, matrix metalloproteinase,
nuclear factor κB, mitogen activated protein kinase, phosphodiesterase-4, janus kinase-signal transducer and activator of transcription, Bruton's
tyrosine kinase, spleen tyrosine kinase, Phosphatidylinositol-3-kinases. The mode of action and their progress in research have been covered in this
review.

Keywords: Disease-modifying anti-rheumatic drugs, Tumor necrosis factor-α converting enzyme, Tumor necrosis factor-α, Janus kinase, Spleen
tyrosine kinase, Phosphatidylinositol-3-kinases (PI3K).

Downloads

Download data is not yet available.

References

Akhter E, Bilal S, Kiani A, Haque U. Prevalence of arthritis in India and Pakistan: A review. Rheumatol Int 2011;31(7):849-55.

Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006;54(1):226-9.

Shapira Y, Agmon-Levin N, Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 2010;6(8):468‑76.

Dewing KA, Setter SM, Slusher BA. Osteoarthritis and rheumatoid arthritis: Pathophysiology, diagnosis and treatment. NPHF 2012;15(10):44-8.

Pope RM. Pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2002;2:527-35.

Dipiro JT, Talbert RL, Yees GC, Matzke GR. Pharmacotherapy Pathophysiological Approach Rheumatoid Arthritis. 6th ed. New York, NY: McGraw-Hill; 2006. p. 1671-83.

Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007;147(2):227-35.

Abbas AB, Lichtman A. In: Basic Immunology, Functions and Disorders of the Immune System. 3rd ed. Philadelphia: Saunders, Elsevier; 2009.

Burmester GR, Feist E, Dörner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10(2):77-88.10. William DA, Lemke TE. Non steroidal anti-inflammatory drug. Foye’s Medicinal Chemistry. 5th ed. Philadelphia: Lippincott, Williams and Wilkins; 2006. p. 751-93.

Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug‑induced damage. Arch Intern Med 1992;152(6):1145-55.

Clà ria J. Cyclooxygenase-2 Biology. Current Pharmaceutical Design 2003;9:2177-90.

El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AA, El-Azab AS, Asiri YA, Eltahir KE. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study. Bioorg Med Chem 2011;19(11):3416-24.

Zarghi A, Arfaei S. Selective COX-2 inhibitors: A review of their structure-activity relationships. Iran J Pharm Res 2011;10(4):655-83.

Kulkarni RG, Achaiah G, Sastry GN. Novel targets for antiinflammatory and antiarthritic agents. Curr Pharm Des 2006;12(19):2437-54.

Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966;153(3731):80-2.

Moss ML, Tavron LS, Nudelman R. Drug Insight: Tumor necrosis factor converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Rev 2008;4(2):300-9.

Beutler B, Cerami A. The common mediator of shock, cachexia, and tumor necrosis. Adv Immunol 1988;42:213-31.

Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31(8):1041-5.

Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35(10):1160-9.

Rose-John S, Schooltink H. CDP-870. Celltech/Pfizer. Curr Opin Investig Drugs 2003;4(5):588-92.

Darlington C. PEG-sTNF-RI. Amgen. Curr Opin Investig Drugs 2003;4(5):583-7.

McComb J, Gould T, Chlipala E, Sennelo G, Frazier J, Kieft G, et al. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy. J Rheumatol 1999;26(6):1347-51.

Kennewell P. Technology evaluation: ISIS-104838, OraSense. Curr Opin Mol Ther 2003;5(1):76-80.

Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-104.

Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti‑TNF-alpha therapies: The next generation. Nat Rev Drug Discov 2003;2(9):736-46.

Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl 2002;65:16-21.

Grootveld M, McDermott MF. BMS-561392. Bristol-Myers Squibb. Curr Opin Investig Drugs 2003;4(5):598-602.

Thabet MM, Huizinga TW. Drug evaluation: Apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 2006;7(11):1014-9.

Fontana A, Hengartner H, Weber E, Fehr K, Grob PJ, Cohen G. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1982;2(2):49-53.

Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1RA Arthritis Study Group. Arthritis Rheum 1996;39(7):1092‑101.

Siegmund B, Zeitz M. Pralnacasan (vertex pharmaceuticals). IDrugs 2003;6(2):154-8.

Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31(6):784-8.

Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46(12):3143-50.

Nishimura A, Akahoshi T, Takahashi M, Takagishi K, Itoman M, Kondo H, et al. Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8.J Leukoc Biol 1997;62(4):444-9.

Ribbens C, André B, Kaye O, Kaiser MJ, Bonnet V, de Groote D, et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw 2000;11(4):669-76.

Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY. Soluble IL‑15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998;160(11):5654-60.

Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73(2):213-24.

Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 2003;10(12):1004-11.

Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74(2):111-22.

Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75(1):69-75.

Nordström D, Lindy O, Lauhio A, Sorsa T, Santavirta S, Konttinen YT. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int 1998;17(5):175-80.

Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-[kappa] B activity. Annu Rev Immunol 2000;18:621-63.

Kopp E, Medzhitov R, Carothers J, Xiao C, Douglas I, Janeway CA, et al. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev 1999;13(16):2059-71.

Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28(4):197-208.

Andreakos E, Smith C, Kiriakidis S, Monaco C, de Martin R, Brennan FM, et al. Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: Implications for therapy. Arthritis Rheum 2003;48(7):1901-12.

Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999;291(1):124-30.

Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BM, Brennan FM. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: Role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 1998;160(2):920-8.

Farzaneh-Far A, Davies JD, Braam LA, Spronk HM, Proudfoot D, Chan SW, et al. A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 2001;276(35):32466-73.

Francischi JN, Yokoro CM, Poole S, Tafuri WL, Cunha FQ, Teixeira MM. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur J Pharmacol 2000;399(2-3):243-9.

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349(20):1907-15.

Zeng X, Ai M, Tian X, Gan X, Shi Y, Song Q, et al. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003;30(7):1451-5.

Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003;3(11):900-11.

Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 2011;18(2):105-10.

Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010;9(12):956-70.

Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 2010;10(6):387-402.

Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011;7(1):41-50.

Ghigo A, Damilano F, Braccini L, Hirsch E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays 2010;32(3):185-96.

Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM. Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 2005;7(16):1-20.

Published

01-03-2015

How to Cite

Das, B., and S. Samanta. “MOLECULAR TARGET AND THERAPEUTIC ASPECTS OF RHEUMATOID ARTHRITIS: A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 2, Mar. 2015, pp. 32-40, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/3963.

Issue

Vol 8 Issue 2 (March - April) 2015

Section

Review Article(s)

The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.